Disclosed positions
| NEWAMSTERDAM PHARMA COMPANY | NAMS | ORDINARY SHARES | $287,738,063 | 8,490,353 | SH | None |
| MAPLIGHT THERAPEUTICS INC | MPLT | COM | $115,634,176 | 3,226,400 | SH | None |
| DYNE THERAPEUTICS INC | DYN | COM | $85,469,766 | 3,848,256 | SH | None |
| VOR BIOPHARMA INC | VOR | COM NEW | $75,800,487 | 4,117,354 | SH | None |
| DAMORA THERAPEUTICS INC | DMRA | COM NEW | $63,490,410 | 2,441,000 | SH | None |
| REPLIMUNE GROUP INC | REPL | COM | $31,088,634 | 2,808,368 | SH | None |
| CRESCENT BIOPHARMA INC. | CBIO | COM | $30,201,336 | 1,677,852 | SH | None |
| AURA BIOSCIENCES INC | AURA | COM | $28,781,803 | 4,053,775 | SH | None |
| ENGENE HOLDINGS INC | ENGN | COM | $16,664,330 | 9,632,561 | SH | None |
| BICYCLE THERAPEUTICS PLC | BCYC | SPONSORED ADS | $14,706,143 | 3,468,430 | SH | None |
| ENGENE HOLDINGS INC | Unresolved | W EXP 10/31/2028 | $834,376 | 2,878,148 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.